Contact Us

Contact us with any questions or comments regarding our novel approach to treating infectious, inflammatory, and degenerative diseases with our plasma gelsolin technology platform.

Name

Phone

Organization

Role

Scientist/Academic Media Investor Other

Message

Stay informed of our latest discoveries and news.

GENERAL NEWS/MEDIA

May, 2020: Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research

May 21, 2020

May, 2020: BioAegis ‘Inflammation Regulator’ Highlighted in CNBC Feature Story on COVID-19

May 11, 2020

April, 2020: BioAegis Demonstrates Gelsolin Therapy Can Quell the Cytokine Storm and Promote Tissue Repair

April 27, 2020

April, 2020: Small NJ Biotech Firm, BioAegis Therapeutics, Accelerating Multiple Clinical Trial Submissions for Severe COVID-19 Pneumonia Patients

April 2, 2020

Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes.

Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Delayed administration of recombinant plasma gelsolin improves survival in a murine model of severe influenza.

Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Susceptible and Penicillin-Resistant Pneumococcal Pneumonia.

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
North Brunswick, NJ

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

JOIN OUR TEAM

Facebook Twitter Linkedin Youtube

Our lead product for severe pneumonia, rhu-pGSN, has application for COVID19.